# BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid Arthritis

> **NCT05659407** · — · UNKNOWN · sponsor: **University of Cagliari** · enrollment: 60 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
- BLyS Polymorphism

## Interventions

- **DRUG:** Belimumab in SLE patients / Rituximab in RA patients

## Key facts

- **NCT ID:** NCT05659407
- **Lead sponsor:** University of Cagliari
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-24
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05659407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05659407, "BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05659407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*